Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy Meeting Abstract
| Authors: | Nastoupil, L. J.; Kamdar, M. K.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López Guillermo, A.; Martinez-Lopez, J.; Novak, U.; Ribrag, V.; Roddie, C.; Waller, E. K.; Feldman, T. A.; Rosenthal, A. C.; Sauter, C.; Von Bonin, M.; Karmali, R.; Montheard, S.; Previtali, A.; Abramson, J. S. |
| Abstract Title: | Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.7526 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: 7526 -- Meeting also presented virtually -- Source: Cinahl |
